Article Text

PDF
Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients
  1. L Teixeira1,
  2. L Mouthon1,
  3. A Mahr1,
  4. A Berezné1,
  5. C Agard2,
  6. M Mehrenberger3,
  7. L-H Noël3,
  8. P Trolliet4,
  9. C Frances5,
  10. J Cabane6,
  11. L Guillevin1
  1. 1
    Internal Medicine Department and Reference Center for Vasculitis and Systemic Sclerosis, Cochin Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), and UPRES EA 4058, Paris-Descartes University, Faculty of Medicine, France
  2. 2
    Department of Internal Medicine, Hôpital Hôtel Dieu, Nantes, France
  3. 3
    INSERM U507, Paris-Descartes University, Necker Hospital, Paris
  4. 4
    Department of Nephrology, Centre Hospitalier Lyon Sud, hospices Civils de Lyon, Lyon, France
  5. 5
    Department of Internal Medicine, Hôpital Tenon, AP-HP, Université Paris 6, Paris, France
  6. 6
    Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Université Paris 6, Paris, France
  1. Luc Mouthon, Department of Internal Medicine, Cochin Hospital, 27 rue du Faubourg Saint-Jacques, 75679 Paris Cedex 14; luc.mouthon{at}cch.aphp.fr

Abstract

Objectives: To describe presentation and outcome of patients with scleroderma renal crisis (SRC).

Methods: SRC was defined as rapidly progressive oliguric renal insufficiency and/or rapidly progressive arterial hypertension occurring during the course of systemic sclerosis (SSc). Chronic dialysis-free survival was analysed using multivariate Cox proportional hazards regression models. The risk for developing SRC associated with corticosteroid (CS) exposure during the preceding 1- or 3-month periods was analysed according to a case–crossover design.

Results: A total of 50 SSc patients aged 53.3 (14.5) (mean (SD)) years were included in the study. SRC occurred between 1979 and 2003, after a mean (SD) disease duration of 27.7 (49.1) months. A total of 43 (86%) patients had diffuse SSc, 5 (10%) had limited cutaneous SSc and 2 (4%) had SSc sine scleroderma. At the time of SRC, 10 (20%) patients were taking angiotensin converting enzyme inhibitors, and mean creatininaemia was 468 (293) μmol/l. A total of 28 (56%) patients required haemodialysis. In all, 11 patients underwent a renal biopsy, all of them had specific vascular lesions of SRC. Multivariate analyses retained age >53 years and normal blood pressure as independent predictors of decreased dialysis-free survival. Exposure to CS prior to SRC was identified in 30 (60%) patients. The odds ratios for developing SRC associated with CS exposure during the preceding 1- or 3-month periods were 24.1 (95% CI 3.0–193.8) and 17.4 (95% CI 2.1–144.0), respectively.

Conclusion: SRC remains associated with severe morbidity and mortality. CS might increase the risk of developing SRC. Further studies are needed to confirm these results.

Statistics from Altmetric.com

Footnotes

  • Funding: LT was supported by Actelion pharmaceutics (Paris, France)

  • Competing interests: None declared

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.